FGFR4 and hepatocellular carcinoma: In addition, inhibitory activity of lenvatinib against the FGF signaling pathway of HCC is prominent, considering the low Median Inhibition Concentration (IC50) value for fibroblast growth factor receptor 4 (FGFR4) [35].